The effect of metformin on apoptosis in a breast cancer presurgical trial

British Journal of Cancer

Volumn 109, Issue 11, 2013, Pages 2792-2797

  Cazzaniga, M ^a   DeCensi, A ^b   Pruneri, G ^a,c   Puntoni, M ^b   Bottiglieri, L ^a   Varricchio, C ^a   Guerrieri Gonzaga, A ^a   Gentilini, O D ^a   Pagani, G ^a   Dell'Orto, P ^a   Lazzeroni, M ^a   Serrano, D ^a   Viale, G ^a,c   Bonanni, B ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; Breast cancer; Insulin resistance; Ki67; Metformin; Neoadjuvant study

Indexed keywords

METFORMIN; PLACEBO;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORE BIOPSY NEEDLE; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NICK END LABELING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KI-67 ANTIGEN; METFORMIN; MIDDLE AGED; NEOADJUVANT THERAPY; PLACEBOS; PREOPERATIVE PERIOD;

EID: 84888870836     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.657     Document Type: Article

References (36)

1. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30: 2593-2600.
2. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M (1998) Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47: 1643-1649. (Pubitemid 28445355)
3. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL (2011) Metformin and incident breast cancer among diabetic women: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 20: 101-111.
4. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care 29: 254-258. (Pubitemid 44106500)
5. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591. (Pubitemid 39025053)
6. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18: 701-705.
7. Decensi A, Gennari A (2011) Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 29: 7-10.
8. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3: 1451-1461.
9. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Lorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewsky JA, Hayes DF. International Ki67 in Breast Cancer Working Group (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast cancer working group. J Natl Cancer Inst 103: 1656-1664.
10. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305. (Pubitemid 40813563)
11. Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A (2013) Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trial. Ann Oncol (in press).
12. Gonzalez-Angulo AM, Meric-Bernstam F (2011) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16: 1695-1700.
13. Goodwin PJ, Ligibel JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27: 3271-3273.
14. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of Metformin in women with early breast cancer. Clin Breast Cancer 8: 501-505.
15. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215-220.
16. Gunter MJ, Hoover DR, Yu H, Wasserteil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101: 48-60.
17. Guppy A, Jamal-Hanjani M, Pickering L (2011) Anticancer effect of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 7: 727-736.
18. Jiralespong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302.
19. Johnson JA, Gale EA (2010) Diabetes, insulin use, and cancer risk: are observational studies part of the solutions or part of the problems? Diabetes 59: 1129-1131.
20. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. New Engl J Med 346: 393-403. (Pubitemid 34437694)
21. Low S, Chin MC, Deurenberg-Yap M (2009) Review on epidemic of obesity. Ann Acad Med Singapore 38: 57-65.
22. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106: 39-47. (Pubitemid 47498088)
23. Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. New Engl J Med 358: 47-54.
24. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135: 821-830.
25. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518. (Pubitemid 38868620)
26. Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17: 328-336. (Pubitemid 44397568)
27. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569-578. (Pubitemid 351232031)
28. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586. (Pubitemid 351793803)
29. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17: 813-822.
30. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Mènard S (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362: 527-533. (Pubitemid 36980657)
31. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18: 374-381. (Pubitemid 40395356)
32. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
33. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273. (Pubitemid 44799743)
34. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174. (Pubitemid 32995375)
35. Zhuang Y, Miskimins WK (2011) Metformin induce both caspase-dependent and poly(ADP-ribose)polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9: 603-615.
36. Yee D (2006) Targeting insulin-like growth factor pathways. Br J Cancer 94: 465-468. (Pubitemid 43289747)